Piper Sandler initiated coverage of Sarepta with an Overweight rating and $157 price target. The analyst likes the prospects for Elevidys to receive an expanded Duchenne muscular dystrophy label on its FDA action date of June 21.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta to replace ShockWave Medical in S&P 400 at open on 6/3
- Airbnb upgraded, Southwest downgraded: Wall Street’s top analyst calls
- RBC downgrades Sarepta on growing expectations into Elevidys decision
- Sarepta downgraded to Sector Perform from Outperform at RBC Capital
- 3 Best Stocks to Buy Now, 5/23/2024, According to Top Analysts